Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
June 7, 2016 7:50 AM EDT
price target on Jefferies analyst Gena Wang maintained her Underperform rating and $7 PT on Sarepta Therapeutic (NASDAQ: SRPT), saying the dystrophin request is the best-case scenario, but they still see a slim chance of approval.
Wang commented, "We see FDA's request for additional... More
June 7, 2016 6:49 AM EDT
Oppenheimer analyst, Christopher Marai, reiterated his Outperform rating after Sarepta Therapeutic (NASDAQ: SRPT) announced the FDA has requested dystrophin data (n=13) from ongoing PROMOVI confirmatory trial of eteplirsen, prior to making an approval decision. SRPT indicated to us biopsies have been completed but... More
June 7, 2016 6:16 AM EDT
Leerink affirms Sarepta (Nasdaq: SRPT) at Underperform with a price target of $5 after the company announced that the U.S. Food and Drug... More
June 6, 2016 5:45 PM EDT
Sarepta Therapeutics (NASDAQ: SRPT) is gaining sharply after the company announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing... More
